/* Pinterest verifcation tag */
December 21, 2022 | Advocacy, Awards
Multiple Sclerosis New Zealand is pleased to award Ingrid Robertson and Joan Perry with Esme Tombleson Awards for 2022, in recognition of their outstanding contributions to people impacted by Multiple Sclerosis nationally. Cantabrian Ingrid Robertson was diagnosed with MS in […]
December 20, 2022 | Advocacy, My Story, Newsletter, Support
As we wind down for the holidays, at Multiple Sclerosis NZ, we have taken a moment to review what a year 2022 has been and celebrate our achievements. We continue to strive for our vision of ‘A world without MS’, […]
November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
November 16, 2022 | Advocacy, Covid-19, Treatments
Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]
November 16, 2022 | Advocacy, Life with MS, Media
Recently, MSNZ made a submission to the Accessibility for New Zealanders Bill. The intention of the proposed bill is to establish “a new legislative framework that addresses systemic accessibility barriers that prevent disabled people, tāngata whaikaha and their whānau, and […]